Welcome to the Breast Tumor Immunology Laboratory (BTIL)
To establish the Dana-Farber and Brigham and Women’s Cancer Center as the pre-eminent institution for breast tumor immunology by elucidating the mechanisms of immune regulation of breast cancer to optimize immunotherapeutic strategies to treat breast cancer thereby reducing recurrence, suffering and mortality.
- To enhance collaborative relationships and opportunities for basic and translational research investigating the immune regulation of breast cancer
- To perform in-depth analysis of animal models and patient samples to efficiently guide rational use and development of immunotherapy modalities for the treatment of breast cancer
- To increase breast cancer patients’ access to trials investigating novel immune-based therapies
Interviews by Dr. Mittendorf
Dr. Mittendorf discusses key takeaways from the Impassion-131 clinical trial investigating first-line atezolizumab in combination with chemotherapy in metastatic triple-negative breast cancer (TNBC) presented at the 2020 ESMO Virtual Congress.
Tweets by @EMittendorfMD
Enjoy the highlights from the 2019 Susan F. Smith Center Executive Council Beyond Boston Luncheon, which features Dr. Mittendorf discussing the success of the Women's Breast Program.
Dr. Mittendorf discusses advances in breast cancer immunotherapy
Building on Recent Successes
Dr. Mittendorf Discusses Immunotherapy Efforts in Breast Cancer
Dr. Mittendorf Discusses Rationale for Updating AJCC Staging System